Formulary Watch |

Formulary Watch covers formularies, pharmacy benefit management companies, drug approvals, and other matters related to medications, their prices and insurance coverage.

Editorial Contact: Denise Myshko: dmyshko@mjhlifesciences.com

All News

FDA Advisory Committee Supports Donanemab in Alzheimer’s Disease
FDA Advisory Committee Supports Donanemab in Alzheimer’s Disease
FDA Advisory Committee Supports Donanemab in Alzheimer’s Disease
June 11, 2024
Committee members, however, also said more data are needed on donanemab to treat patients in underrepresented patient groups, including Latin American and African American patients and special populations such as Down syndrome.
steph photographies-stock.adobe.com
FDA Sets Review Date for Tagrisso for Specific Lung Cancer Mutations
FDA Sets Review Date for Tagrisso for Specific Lung Cancer Mutations
June 10, 2024
Tagrisso, which is already available to treat patients with non-small cell lung cancer and EGFR mutations, is being reviewed by the FDA for patients with this cancer and exon 19 deletions or exon 21 mutations.
Dr_Microbe-stock.adobe.com
 FDA Assigns Goal Date for Maintenance Dosing of Leqembi
FDA Assigns Goal Date for Maintenance Dosing of Leqembi
June 10, 2024
The FDA is considering a monthly IV maintenance dose of Leqembi to treat people with Alzheimer’s disease. The action date is set for Jan. 25, 2025.
ICER Releases List of Drugs for Fair Access Review
ICER Releases List of Drugs for Fair Access Review
ICER Releases List of Drugs for Fair Access Review
June 7, 2024
Included in this review will be 11 drugs that ICER assessed for cost-effectiveness in 2022. New this year is an assessment for consumer accessibility of drugs, including the burdens of prior authorization and patient cost-sharing measures.
Reading a magazine | image credit: fotofabrika - stock.adobe.com
What We’re Reading: Counterfeit Ozempic
What We’re Reading: Counterfeit Ozempic
June 6, 2024
Vanity Fair shines a light on how fake Ozempic and other semaglutide products have found their way into the U.S. supply chain.
 Stepan Popov-stock.adobe.com
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5, 2024
Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
LucyRx Partners with Employers for a New Kind of PBM
LucyRx Partners with Employers for a New Kind of PBM
LucyRx Partners with Employers for a New Kind of PBM
May 31, 2024
LucyRx will begin providing pharmacy benefit services to self-insured employers, covering about half a million lives, beginning in January 2025.
FDA Approves Non-Stimulant ADHD Medication
FDA Approves Non-Stimulant ADHD Medication
FDA Approves Non-Stimulant ADHD Medication
May 30, 2024
Onyda XR is a liquid form of clonidine that can be used as monotherapy or as adjunctive therapy for patients 6 years of age and older with ADHD.
 WrightStudio-stock.adobe.com
Global Spending on Cancer Drugs to Increase to $409 Billion
Global Spending on Cancer Drugs to Increase to $409 Billion
May 28, 2024
In the United States, spending on oncology therapies rose to $99 billion in 2023, and is expected to grow to nearly $180 billion in 2028, finds a recent report by IQVIA Institute for Human Data Science.
 Ольга Тернавская-stock.adobe.com
Updated: FDA Approves First Interchangeable Biosimilars to Eylea
Updated: FDA Approves First Interchangeable Biosimilars to Eylea
May 21, 2024
Yesafili and Opuviz are approved to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Optum Rx to Offer Guarantee-Based Pricing Model
Optum Rx to Offer Guarantee-Based Pricing Model
Optum Rx to Offer Guarantee-Based Pricing Model
May 20, 2024
The new program will launch in January 2025 and provide plan sponsors greater predictability of pharmacy spend.
MilletStudio-stock.adobe.com
FDA Sets Review Date for Gene Therapy for Enzyme Deficiency
FDA Sets Review Date for Gene Therapy for Enzyme Deficiency
May 14, 2024
Upstaza is a one-time gene therapy to treat patients 18 months and older with AADC deficiency. It has a review date of Nov. 13, 2024.
© 2024 MJH Life Sciences

All rights reserved.